DISTRIBUTION OF CA 125 IN ADENOCARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY OF 481 CASES

被引:75
作者
LOY, TS
QUESENBERRY, JT
SHARP, SC
机构
[1] Department of Pathology, Missouri Univ. Health Sciences Ctr., Columbia, MO 65212, One Hospital Drive
关键词
CA-125; IMMUNOHISTOCHEMISTRY; GLYCOPROTEIN; ADENOCARCINOMAS;
D O I
10.1093/ajcp/98.2.175
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To determine the distribution of CA 125 in adenocarcinomas, formalin-fixed, paraffin-embedded tissue from 481 cases of adenocarcinoma from a variety of primary sites were studied using a monoclonal antibody to CA 125 (B27.1) and an avidin-biotin immunohistochemical technique. Positive reactivity was most common in adenocarcinomas of the endocervix, ovary, and endometrium (61% to 94%). However, relatively frequent positive reactions also were seen in adenocarcinomas of the pancreas (48%) and bile ducts (56%). Adenocarcinomas of the breast, lung, thyroid, distal esophagus/stomach, and liver (hepatocellular carcinoma) showed positive reactions in 7% to 20% of cases. Staining of rare tumor cells was seen in 2 of 45 colonic adenocarcinomas and in 1 of 61 prostatic adenocarcinomas. No reactivity was seen in the 54 renal cell carcinomas studied. Although CA 125 is most commonly present in gynecologic adenocarcinomas, it is also produced by some adenocarcinomas from many other sites. Immunostaining for CA 125 may be helpful in ruling out renal cell carcinoma in certain clinical settings.
引用
收藏
页码:175 / 179
页数:5
相关论文
共 39 条
[1]   CA125 AS A SERUM MARKER FOR POOR PROGNOSIS IN OVARIAN MALIGNANCIES [J].
ALVAREZ, RD ;
TO, A ;
BOOTS, LR ;
SHINGLETON, HM ;
HATCH, KD ;
HUBBARD, J ;
SOONG, SJ ;
POTTER, ME .
GYNECOLOGIC ONCOLOGY, 1987, 26 (03) :284-289
[2]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[3]  
DAVIS HM, 1986, CANCER RES, V46, P6143
[4]   ANTIGEN-DETECTION BY THE MONOCLONAL-ANTIBODIES CA-19-9 AND CA-125 IN NORMAL AND TUMOR-TISSUE AND PATIENTS SERA [J].
DIETEL, M ;
ARPS, H ;
KLAPDOR, R ;
MULLERHAGEN, S ;
SIECK, M ;
HOFFMANN, L .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1986, 111 (03) :257-265
[5]  
DUK JM, 1990, CANCER, V65, P1830, DOI 10.1002/1097-0142(19900415)65:8<1830::AID-CNCR2820650828>3.0.CO
[6]  
2-S
[7]   CA-125 - A USEFUL MARKER IN ENDOMETRIAL CARCINOMA [J].
DUK, JM ;
AALDERS, JG ;
FLEUREN, GJ ;
DEBRUIJN, HWA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (05) :1097-1102
[8]   CLINICAL-SIGNIFICANCE OF SERUM CA125 VALUES IN PATIENTS WITH CANCERS OF THE DIGESTIVE-SYSTEM [J].
HAGA, Y ;
SAKAMOTO, K ;
EGAMI, H ;
YOSHIMURA, R ;
MORI, K ;
AKAGI, M .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1986, 292 (01) :30-34
[10]   USE OF AVIDIN-BIOTIN-PEROXIDASE COMPLEX (ABC) IN IMMUNOPEROXIDASE TECHNIQUES - A COMPARISON BETWEEN ABC AND UNLABELED ANTIBODY (PAP) PROCEDURES [J].
HSU, SM ;
RAINE, L ;
FANGER, H .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (04) :577-580